ADMA Biologics (NASDAQ:ADMA) Announces Quarterly Earnings Results, Hits Expectations

ADMA Biologics (NASDAQ:ADMA) released its earnings results on Wednesday. The biotechnology company reported $0.16 EPS for the quarter, meeting the consensus estimate of $0.16, Zacks reports. The firm had revenue of $134.22 million for the quarter, compared to analyst estimates of $131.20 million. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The business’s quarterly revenue was up 12.0% compared to the same quarter last year. During the same period last year, the firm earned $0.15 EPS. ADMA Biologics updated its FY 2026 guidance to EPS and its FY 2025 guidance to EPS.

ADMA Biologics Trading Up 3.5%

Shares of NASDAQ ADMA traded up $0.49 during trading on Friday, reaching $14.52. The company had a trading volume of 4,568,292 shares, compared to its average volume of 3,228,769. The stock has a market cap of $3.46 billion, a P/E ratio of 16.88 and a beta of 0.40. The company’s fifty day moving average price is $15.43 and its 200-day moving average price is $17.92. The company has a quick ratio of 2.78, a current ratio of 5.33 and a debt-to-equity ratio of 0.21. ADMA Biologics has a 12 month low of $13.50 and a 12 month high of $25.67.

Institutional Trading of ADMA Biologics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. First Light Asset Management LLC bought a new stake in shares of ADMA Biologics in the 2nd quarter valued at $17,338,000. State Street Corp grew its holdings in ADMA Biologics by 5.6% during the 2nd quarter. State Street Corp now owns 12,078,505 shares of the biotechnology company’s stock worth $219,950,000 after acquiring an additional 637,727 shares during the period. Balyasny Asset Management L.P. lifted its stake in shares of ADMA Biologics by 154.5% in the 2nd quarter. Balyasny Asset Management L.P. now owns 971,414 shares of the biotechnology company’s stock valued at $17,689,000 after purchasing an additional 589,707 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of ADMA Biologics by 59.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 816,590 shares of the biotechnology company’s stock valued at $16,201,000 after purchasing an additional 305,064 shares in the last quarter. Finally, Raymond James Financial Inc. grew its stake in ADMA Biologics by 15.3% during the second quarter. Raymond James Financial Inc. now owns 1,522,045 shares of the biotechnology company’s stock worth $27,716,000 after purchasing an additional 202,242 shares during the period. Institutional investors and hedge funds own 75.68% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings downgraded ADMA Biologics from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, October 24th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $27.67.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.